Predictive Oncology (NASDAQ:POAI) Stock Price Passes Below Two Hundred Day Moving Average of $2.42

Shares of Predictive Oncology Inc. (NASDAQ:POAI) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.42 and traded as low as $0.89. Predictive Oncology shares last traded at $0.89, with a volume of 216,920 shares changing hands.

Predictive Oncology Price Performance

The company’s 50 day simple moving average is $1.48 and its 200 day simple moving average is $2.42. The stock has a market cap of $3.67 million, a P/E ratio of -0.24 and a beta of 1.33.

Predictive Oncology (NASDAQ:POAI) last posted its earnings results on Tuesday, May 14th. The medical instruments supplier reported ($1.04) earnings per share for the quarter. The business had revenue of $0.42 million for the quarter. Predictive Oncology had a negative return on equity of 151.51% and a negative net margin of 754.13%.

Hedge Funds Weigh In On Predictive Oncology

An institutional investor recently bought a new position in Predictive Oncology stock. Carnegie Mellon University acquired a new position in shares of Predictive Oncology Inc. (NASDAQ:POAI) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,358 shares of the medical instruments supplier’s stock, valued at approximately $34,000. Predictive Oncology accounts for about 0.0% of Carnegie Mellon University’s holdings, making the stock its 5th largest holding. Carnegie Mellon University owned about 0.26% of Predictive Oncology at the end of the most recent quarter. 9.04% of the stock is owned by institutional investors.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.